# Retatrutide: Research Overview — Integrative Peptide > A literature summary of retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple receptor agonist. Covers mechanism, Phase 2 obesity, diabetes, and liver-disease trial results, and cited safety cautions. A triple GIP/GLP-1/glucagon agonist that posted a -24.2% mean body-weight change in its pivotal Phase 2 obesity trial — still awaiting Phase 3 confirmation and regulatory approval. ## The short version Retatrutide, also called LY3437943, is a single lab-made peptide that switches on three different hormone receptors at once: GLP-1, GIP, and glucagon. The first two are the same receptors single- and dual-agonist compounds use to cut appetite and improve blood sugar; the third, glucagon, is unusual for this drug class because it can increase how many calories the body burns, not just how much a person wants to eat. In its largest Phase 2 obesity trial, once-weekly retatrutide produced an average -24.2% body-weight change over 48 weeks — the biggest number reported for any incretin-class compound to date [9]. It is still investigational: Phase 3 trials, called TRIUMPH, are running now, and no regulator has approved it. Every figure on this page comes from a published clinical trial; none of it is a recommended dose or a treatment plan for any individual, and material sold outside a registered trial cannot be verified as authentic retatrutide. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone (molecular formula C221H342N46O68, free acid) and acylated with a C20 fatty-diacid arm that drives albumin binding, extending its circulating half-life to roughly six days and enabling once-weekly subcutaneous dosing [11]. Cryo-EM structures published in 2024 resolved how it engages all three of its target receptors — GLP-1R, GIPR, and GCGR — at atomic resolution (2.68, 3.26, and 2.84 angstroms respectively). Relative to the native hormones, it is roughly 8.9 times more potent at the GIP receptor but only 0.3 and 0.4 times as potent at the glucagon and GLP-1 receptors, and the loop that contacts each receptor adopts a rigid alpha-helix at GLP-1R and GCGR but a flexible, floppier shape at GIPR [7] — structural evidence that this is a molecule engineered to engage three receptors differently, not identically. ## How it works Retatrutide inherits the appetite-suppressing, insulin-boosting pharmacology of GLP-1 and GIP receptor agonism and adds a third, distinguishing input: controlled glucagon receptor activation. Glucagon's usual job is to tell the liver to release stored glucose; in most contexts that would work against a diabetes drug. But layered on top of GLP-1/GIP-driven insulin support, mild glucagon receptor stimulation instead appears to raise energy expenditure — through brown-fat thermogenesis and fatty-acid oxidation — with little net effect on blood glucose. The practical result is a compound that pushes on both sides of the energy-balance equation at once: eating less through the GLP-1/GIP arms, and, per the proposed mechanism, burning somewhat more through the glucagon arm [6]. Post-hoc metabolic profiling supports a real biochemical shift alongside the weight change: across two Phase 2 trials (n=282 in obesity, n=213 in type 2 diabetes), higher retatrutide doses were associated with reduced triglycerides — particularly triglycerides enriched in short-chain and saturated fatty-acid side chains — and improvements in insulin-resistance biomarkers (branched-chain amino acids, 2-hydroxybutyrate, urate) pointed in a direction generally associated with lower cardiovascular risk; a fatty-acid-oxidation biomarker cluster statistically mediated about 23.2% of the weight-reduction response in participants without type 2 diabetes [12]. ## What the research shows *Structural basis for triple agonism.* Cryo-EM work resolved retatrutide bound to all three of its target receptor complexes, confirming distinct binding geometries at each and quantifying its relative potency at roughly 8.9x native GIP at GIPR versus 0.3x and 0.4x at GCGR and GLP-1R [7]. *Phase 2 obesity trial.* In 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean -24.2% body-weight change over 48 weeks versus -2.1% with placebo. Gastrointestinal adverse events were dose-related and mostly mild-to-moderate, and a dose-dependent heart-rate increase peaked around week 24 [9]. *Phase 2 type 2 diabetes trial.* In 281 adults with type 2 diabetes over 36 weeks, retatrutide 12 mg lowered HbA1c by -2.02% at 24 weeks versus -0.01% with placebo, and reduced body weight by 16.94% at 36 weeks versus 3.00% with placebo; gastrointestinal adverse events occurred in 35% of participants, with no severe hypoglycemia and no deaths reported [10]. *Phase 2a metabolic liver disease substudy.* In 98 adults with obesity or overweight and metabolic dysfunction-associated steatotic liver disease, retatrutide 12 mg reduced relative liver fat by -82.4% at 24 weeks, with 86% of participants reaching normal, under-5%, liver fat; the reduction was sustained to 48 weeks at -86.0% [8]. *First-in-human Phase 1b.* In 72 adults with type 2 diabetes, retatrutide showed an approximately six-day half-life supporting once-weekly dosing; the highest-dose group lost a placebo-adjusted 8.96 kg over 12 weeks, and daily glucose fell by 2.8 mmol/L at the 3 mg dose. Treatment-emergent adverse events occurred in 63% of participants, predominantly gastrointestinal, within an overall acceptable safety profile [11]. *Metabolomic and lipidomic profiling.* Post-hoc analysis of two Phase 2 trials found higher retatrutide doses associated with reduced triglycerides and favorable shifts in insulin-resistance biomarkers, with a fatty-acid-oxidation cluster mediating roughly 23.2% of the weight-reduction response in non-diabetic participants [12]. ## Reported effects, cautions & safety Retatrutide has an active online research-use community, and the reports below are **anecdotal, not clinical evidence** — unverified self-reports with no confirmed doses and no clinical oversight, offered here for context alongside the trial data above, not as a substitute for it. *Reported benefits (anecdotal, not clinical evidence):* the most frequently repeated theme is a near-total silencing of intrusive food-related thoughts, described in community threads as food noise going quiet, alongside weight reduction that community members describe as faster than their experience with other incretin-class compounds, broadly in line with the trial trajectory. A subset describe a distinct warmth or mild thermogenic sensation, widely attributed in community discussion to the glucagon-receptor arm, and some describe a lighter mood or improved relationship with food. *Reported side effects (anecdotal, not clinical evidence):* nausea in the hours after injection is the most common complaint, described as peaking four to eight hours post-dose and easing after the first few weeks — a pattern that maps onto the dose-related GI signal in the Phase 2 program [9]. An elevated resting heart rate, sometimes described as 5-15 bpm above baseline on wearable devices, is a recurring community theme that corresponds to the dose-dependent heart-rate increase documented in trials [9]. Sulfur burps, constipation, early fatigue, occasional sleep disruption, and mild injection-site itching round out the commonly described profile. *Cited cautions:* retatrutide is an unapproved investigational compound; material obtained outside a registered trial has no verified identity, purity, or sterility, and the FDA issued dozens of warning letters to vendors of unauthorized retatrutide product in 2025 [6][9]. Dose-dependent gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 obesity trial [9]. The compound produces a dose-dependent increase in resting heart rate, a mechanistically expected consequence of glucagon-receptor-driven cardiac chronotropy, and a dedicated cardiovascular-outcomes trial is ongoing but has not reported results [9]. Combined with insulin or sulfonylurea medications, retatrutide's insulin-augmenting effect can raise hypoglycemia risk and may require dose adjustment of those other medications [10][11]. Rapid, large-magnitude weight loss of the kind seen in trials typically includes some reduction in lean mass alongside fat mass — a pattern documented across the broader incretin-class literature — making adequate protein intake and resistance training a reasonable precaution, though body-composition data specific to retatrutide's ongoing Phase 3 program have not yet been published. Finally, the pivotal cardiovascular- and kidney-outcomes trials are still running as of mid-2026, so long-term safety and the durability of weight loss after stopping remain open questions [6]. ## Where it fits in metabolic research Retatrutide is the lead data set on this desk for a simple reason: no other compound here has produced a larger weight-loss number in a controlled trial. Its -24.2% at 48 weeks [9] sits well above [semaglutide's](/semaglutide) -14.9% at 68 weeks [16], and the mechanistic story — three receptors rather than one — offers a coherent explanation for why. But 'largest number so far' and 'approved medicine' are different claims, and this desk keeps them separate: semaglutide has a decade-plus, multi-indication regulatory record; retatrutide has two pivotal Phase 2 trials and an ongoing Phase 3 program. [AOD-9604's](/aod-9604) story is a useful counterweight to keep in view alongside it — a compound whose rodent-model mechanism was every bit as clean and whose human efficacy trial did not confirm it. See the [comparison page](/compare) for the four side by side. ![Retatrutide research illustration — abstract triple-receptor agonist motifs in teal noir](/images/retatrutide.webp) --- Integrative Peptide reads the primary literature so the numbers can carry the argument — an independent research index, not a clinic, a vendor, or a source of medical advice.